Systemic Therapy for Hepatocellular Carcinoma: Latest Advances

Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction of the molecular targeted agent sorafenib in 2007. Although sorafenib expanded the treatment options for extrahepatic spread (EHS) and vascular invasion, making long-term survival of patients with adva...

Descripción completa

Detalles Bibliográficos
Autor principal: Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266463/
https://www.ncbi.nlm.nih.gov/pubmed/30380773
http://dx.doi.org/10.3390/cancers10110412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266463/
https://www.ncbi.nlm.nih.gov/pubmed/30380773
http://dx.doi.org/10.3390/cancers10110412

Ejemplares similares